QuantaBrain
Pisa · Founded 2023
About QuantaBrain
QuantaBrain has developed a novel and patented deep learning architecture capable of extracting neurofunctional biomarkers for 11 distinct neuropsychiatric conditions from just 2 minutes of resting-state functional MRI. By collecting pre- and post-treatment rs-fMRI data during Phase I trials, the model can be fine-tuned to predict individual responses to new compounds. This enables pharmaceutical companies to optimize their clinical trials through large-scale simulations of drug efficacy using internal data (prior to patient enrollment), enrichment strategies to select likely responders, and drug repurposing opportunities. Pharma companies partnering with QuantaBrain can save up to $116M per approved drug.
Company Facts
- Founded: 2023
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.0M
- Funding stage: Seed
- Last round: Grant (Jun 2025)
- Website: https://quantabrain.org/
- Phone: +39 3391500442
Industries & Categories
Artificial Intelligence (AI), Health Diagnostics, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/quantabrain-119003 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.